Molecular-targeted drugs with an anti-VEGF effect act on tumor blood vessels to improve the vascular permeability; reduce the tumor interstitial pressure; improve the drug delivery; enhance the treatment efficacy [34]; and suppress the effect of the transient increase of VEGF immediately after the occurrence of TACE-related ischemia, which is considered as one of the causes of tumor exacerbation [33,34,37,38]. The gene discussed is VEGFA; the disease is ischemia.